Analysts think CUE stock price could increase by 554%
Jun 12, 2025, 11:25 AM
11.88%
What does CUE do
Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
4 analysts think CUE stock price will increase by 554.06%. The current median analyst target is $4.08 compared to a current stock price of $0.62. The lowest analysts target is $2.02 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
